참고문헌
- An D , Kewalramani G, Chan JK Y et al (2006). Diabetologia, 49, 2174-84. https://doi.org/10.1007/s00125-006-0338-9
- Avila MA, Berasain C, Sangro B, et al (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84. https://doi.org/10.1038/sj.onc.1209550
- Bailey CJ, Turner RC (1996). Metformin. N Engl J Med, 334, 574-9. https://doi.org/10.1056/NEJM199602293340906
- Bolster DR, Crozier SJ, Kimball SR, et al (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem, 277, 977-80.
- Bowker SL, Majumdar SR, Veugelers P et al (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8. https://doi.org/10.2337/diacare.29.02.06.dc05-1558
- Buzzai M, Jones RG, Amaravadi RK (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67, 6745-52. https://doi.org/10.1158/0008-5472.CAN-06-4447
- Cantrell LA, Zhou C, Mendivil A, et al (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecologic Oncology, 116, 92-8. https://doi.org/10.1016/j.ygyno.2009.09.024
- Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapie on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77. https://doi.org/10.1007/s00125-009-1440-6
- Daniels D, Grytdal S, Wasley A (2009). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ, 58, 1-27.
- Dowling RJO, Zakikhani M, Fantus IG, et al (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12. https://doi.org/10.1158/0008-5472.CAN-07-2310
- Duncan B, Schmidt MI (2009). Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research. Diabetes Care, 32, 1748-50. https://doi.org/10.2337/dc09-1183
- Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. https://doi.org/10.1136/bmj.38415.708634.F7
- Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20. https://doi.org/10.1007/s10549-010-1224-1
- Gotlieb WH, Saumet J, Beauchamp MC (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 110, 246-50. https://doi.org/10.1016/j.ygyno.2008.04.008
- Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6. https://doi.org/10.1038/sj.onc.1204091
- Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11. https://doi.org/10.1158/0008-5472.CAN-09-2994
- Holland EC, Sonenberg N, Pandolfi PP, et al (2004). Signaling control of mRNA translation in cancer pathogenesis. Oncogene, 23, 3138-44. https://doi.org/10.1038/sj.onc.1207590
- Huang X, Wullschleger S, Shpiro N, et al (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 412, 211-21. https://doi.org/10.1042/BJ20080557
- Kahn BB, Alquier T, Carling D, et al (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 1, 15-25. https://doi.org/10.1016/j.cmet.2004.12.003
- Kalender A, Selvaraj A, Kim SY, et al (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab, 11, 390-401. https://doi.org/10.1016/j.cmet.2010.03.014
- Lee MS, Hsu CC, Wahlqvist M, et al (2011). Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 11, 20. https://doi.org/10.1186/1471-2407-11-20
- Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5. https://doi.org/10.2337/dc08-2175
- Li DH, Ching JS, Yeung M, et al (2009). Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137, 482-8. https://doi.org/10.1053/j.gastro.2009.04.013
- Sahra IB, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86. https://doi.org/10.1038/sj.onc.1211024
- Schneider MB, Matsuzaki H, Haorah J, et al (2001). Prenvention of pancreatic cancer induction in hamsters by metformin. Gastroenterology, 120, 1263-70. https://doi.org/10.1053/gast.2001.23258
- Soranna D, Scotti L, Zambon A (2012). Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. The Oncologist, 17, 1083-7159.
- Wang LW, Li ZS, Zou DW, et al (2008). Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol, 14, 7192-8. https://doi.org/10.3748/wjg.14.7192
- Wright JL, Stanford JL (2009). Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control, 20, 1617-22. https://doi.org/10.1007/s10552-009-9407-y
- Wullschleger S, Loewith R, Hall MN (2006). TOR signaling in growth and metabolism. Cell, 124, 471-84. https://doi.org/10.1016/j.cell.2006.01.016
- Yu Y, Sato JD (1999). MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol, 178, 235-46. https://doi.org/10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S
- Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Res, 66, 10269-73. https://doi.org/10.1158/0008-5472.CAN-06-1500
- Zhu Z, Jiang W, Thompson MD, et al (2011). Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog, 10, 17. https://doi.org/10.4103/1477-3163.83043
피인용 문헌
- Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo vol.30, pp.5, 2013, https://doi.org/10.3892/or.2013.2718
- The mTOR pathway in hepatic malignancies vol.58, pp.2, 2013, https://doi.org/10.1002/hep.26323
- Puerarin inhibits growth and induces apoptosis in SMMC-7721 hepatocellular carcinoma cells vol.10, pp.5, 2014, https://doi.org/10.3892/mmr.2014.2512
- Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells vol.10, pp.6, 2014, https://doi.org/10.3892/mmr.2014.2614
- Diabetes - Increased Risk for Cancers through Chromosomal Aberrations? vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4571
- Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells vol.9, pp.6, 2014, https://doi.org/10.3892/mmr.2014.2097
- Anti-Tumor Effects of Metformin in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis vol.10, pp.6, 2015, https://doi.org/10.1371/journal.pone.0127967
- Effects of Metformin on Cell Kinetic Parameters of MCF-7 Breast Cancer Cells in Vitro vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2351
- Impact of insulin resistance on hepatocellular carcinoma vol.56, pp.4, 2015, https://doi.org/10.2957/kanzo.56.127
- Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria‑mediated pathway pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3450
- Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro vol.11, pp.5, 2016, https://doi.org/10.3892/etm.2016.3143
- Metformin Synergistically Enhances Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A Against Osteosarcoma Cell Line vol.32, pp.4, 2013, https://doi.org/10.1089/dna.2012.1926
- Novel approaches to drug discovery for the treatment of type 2 diabetes vol.9, pp.9, 2014, https://doi.org/10.1517/17460441.2014.941352
- Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo vol.51, pp.5, 2017, https://doi.org/10.3892/ijo.2017.4134
- studies vol.13, pp.13, 2018, https://doi.org/10.2217/nnm-2017-0386
- Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis vol.2019, pp.1687-8345, 2019, https://doi.org/10.1155/2019/7570146
- Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study pp.1573-4978, 2019, https://doi.org/10.1007/s11033-019-04653-6